Reynolds de Sousa T, Ribeiro M, Novais F. Assessment of Innovative Pharmacological Targets in Schizophrenia. Curr Treat Options Psychiatry. 2024;11(3):203–17.

Article  Google Scholar 

Szkultecka-Dębek M, Walczak J, Augustyńska J, Miernik K, Stelmachowski J, Pieniążek I, Obrzut G, Pogroszewska A, Paulić G, Damir M, Antolić S. Epidemiology and treatment guidelines of negative symptoms in schizo-phrenia in central and eastern Europe: a literature review. Clin Pract Epidemiol mental health: CP EMH. 2015;11:158.

Article  PubMed  PubMed Central  Google Scholar 

Jarab A, Al-Qerem W, Khdour A, Awadallah H, Mimi Y, Khdour M. Novel pharmaceutical treatment approaches for schizophrenia: a systematic literature review. Eur J Clin Pharmacol 2025;14:1–7.

Hall J. Schizophrenia–new treatments soon. Br J Psychiatry. 2025;226(3):127–8.

Article  PubMed  Google Scholar 

Anwar A, Mustafa AM, Abdou K, Rabie A, El-Shiekh M, El-Dessouki RA. A comprehensive review on schizophrenia: epidemiology, pathogenesis, diagnosis, conventional treatments, and proposed natural compounds used for management. Naunyn-Schmiedeberg’s Archives of Pharmacology. Jun. 2025;13:1–25.

Google Scholar 

Yang H, Sun W, Yang M, Li J, Zhang J, Zhang X. Variations to plasma H2O2 levels and TAC in chronical medicated and treatment-resistant male schizophrenia patients: Correlations with psychopathology. Schizophrenia. 2024;10(1):45.

Article  PubMed  PubMed Central  Google Scholar 

Zhang K, Zou L, Cai Y. Progress in the study of oxidative stress damage in patients with schizophrenia: challenges and opportunities. Front Psychiatry. 2025;16:1505397.

Article  PubMed  PubMed Central  Google Scholar 

Herniman SE, Wood SJ, Khandaker G, Dazzan P, Pariante CM, Barnes NM, Krynicki CR, Nikkheslat N, Vincent RC, Roberts A, Giordano A. Network analysis of inflammation and symptoms in recent onset schizophrenia and the influence of minocycline during a clinical trial. Translational psychiatry. 2023;13(1):297.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Lv H, Guo M, Guo C, He K. The interrelationships between cytokines and schizophrenia: a systematic review. Int J Mol Sci. 2024;25(15):8477.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Dash UC, Bhol NK, Swain SK, Samal RR, Nayak PK, Raina V, et al. Oxidative stress and inflammation in the pathogenesis of neurological disorders: mechanisms and implications. Acta Pharm Sin B. 2025;15(1):15–34.

Article  CAS  PubMed  Google Scholar 

Morén C, Treder N, Martínez-Pinteño A, Rodríguez N, Arbelo N, Madero S, Gómez M, Mas S, Gassó P, Parellada E. Systematic review of the therapeutic role of apoptotic inhibitors in neurodegeneration and their potential use in schizophrenia. Antioxidants. 2022;11(11):2275.

Article  PubMed  PubMed Central  Google Scholar 

Saint-Georges Z, MacDonald J, Al-Khalili R, Hamati R, Solmi M, Keshavan MS, Tuominen L, Guimond S. Cholinergic system in schizophrenia: A systematic review and meta-analysis. Mol Psychiatry. 2025;20:1–5.

Google Scholar 

Metz CN, Brines M, Pavlov VA. Bridging cholinergic signalling and inflammation in schizophrenia. Schizophrenia. 2024;10(1):51.

Article  PubMed  PubMed Central  Google Scholar 

Shaju A, Mishra A, Mohapatra D, Srinivasan A, Maiti R. Efficacy and safety of cholinergic modulators in patients with schizophrenia: meta-analysis of randomised controlled trials. Br J Psychiatry. 2025;2:1–1.

Google Scholar 

Benvenutti R, Gallas-Lopes M, Marcon M, Reschke CR, Herrmann AP, Piato A. Glutamate NMDA receptor antagonists with relevance to schizophrenia: a review of zebrafish behavioral studies. Curr Neuropharmacol. 2022;20(3):494–509.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Moghaddam AH, Estalkhi FM, Jelodar SK, Hasan TA, Farhadi-Pahnedari S, Karimian M. Neuroprotective effects of alpha-pinene against behavioral deficits in ketamine-induced mice model of schizophrenia: focusing on oxidative stress status. IBRO Neurosci Rep. 2024;16:182–9.

Article  Google Scholar 

Phensy A, Driskill C, Lindquist K, Guo L, Jeevakumar V, Fowler B, Du H, Kroener S. Antioxidant treatment in male mice prevents mitochondrial and synaptic changes in an NMDA receptor dysfunction model of schizophrenia. ENeuro. 2017;4(4).

Uruaka CI, Ben-Azu B, Omeiza NA, Chidebe EO, Ajayi AM, Lemii CB, Nonju TI, Georgewill UO, Georgewill OA. Inhibition of oxidative stress, neuroinflammatory cytokines, and protein expressions contributes to the antipsychotic effects of geraniol in mice with ketamine-induced schizophrenia. J Neuroimmune Pharmacol. 2025;20(1):1–23.

Google Scholar 

Ishola IO, Ben-Azu B, Adebayo OA, Ajayi AM, Omorodion IL, Edje KE, et al. Prevention and reversal of ketamine-induced experimental psychosis in mice by the neuroactive flavonoid, hesperidin: the role of oxidative and cholinergic mechanisms. Brain Res Bull. 2021;177:239–51.

Article  CAS  PubMed  Google Scholar 

Saxena B. Eugenol as Neuro-Phytomedicine: Recent Trends Pertaining to the Treatment of Neurological Disorders. NeuroPhytomedicine. Jan. 2024;29:187–204.

Google Scholar 

Tripathy NS, Sahoo L, Paikray SK, Dilnawaz F. Eugenol: the phytocompound’s potential biological applications. BioNanoScience. 2024;14(4):4044–55.

Article  Google Scholar 

Parween N, Jabeen A, Prasad B. Eugenol-a review of a versatile molecule with remarkable pharmacological properties. J Adv Sci Res. 2021;12(02):8–12.

CAS  Google Scholar 

Barboza JN, da Silva Maia Bezerra Filho C, Silva RO, Medeiros JV, de Sousa DP. An overview on the anti-inflammatory potential and antioxidant profile of eugenol. Oxid Med Cell Longev. 2018;2018(1):3957262.

Article  PubMed  PubMed Central  Google Scholar 

Kakkar A, Singh H, Anand A, Chopra H, Mishra AK. Neuroprotective Effects of Eugenol in Alzheimer’s Disease: Mitigating Oxidative Stress, Inflammation and Amyloid Plaques. Curr Pharm Design. 2025.

Irie Y. Effects of eugenol on the central nervous system: its possible application to treatment of Alzheimer’s disease, depression, and Parkinson’s disease. Curr Bioact Compd. 2006;2(1):57–66.

Article  CAS  Google Scholar 

Sargsyan T, Simonyan HM, Stepanyan L, Tsaturyan A, Vicidomini C, Pastore R, Guerra G, Roviello GN. Neuroprotective Properties of Clove (Syzygium aromaticum): State of the Art and Future Pharmaceutical Applications for Alzheimer’s Disease. Biomolecules. 2025;15(3):452.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Vora U, Vyas VK, Wal P, Saxena B. Effects of eugenol on the behavioral and pathological progression in the MPTP-induced Parkinson’s disease mouse model. Drug Discov Ther. 2022;16(4):154–63.

Article  CAS  PubMed  Google Scholar 

Horka P, Langova V, Hubeny J, Vales K, Chrtkova I, Horacek J. Open field test for the assessment of anxiety-like behavior in Gnathonemus petersii fish. Front Behav Neurosci. 2024;17:1280608.

Article  PubMed  PubMed Central  Google Scholar 

Oyovwi MO, Ben-Azu B, Edesiri TP, Victor E, Rotu RA, Ozegbe QE, Nwangwa EK, Atuadu V, Adebayo OG. Kolaviron abates busulfan-induced episodic memory deficit and testicular dysfunction in rats: the implications for neuroendopathobiological changes during chemotherapy. Biomed Pharmacother. 2021;142:112022.

Article  CAS  PubMed  Google Scholar 

Kim DG, Gonzales EL, Kim S, Kim Y, Adil KJ, Jeon SJ, et al. Social interaction test in home cage as a novel and ethological measure of social behavior in mice. Exp Neurobiol. 2019;28(2):247.

Article  PubMed  PubMed Central  Google Scholar 

Hassanzadeh-Taheri M, Ahmadi-Zohan A, Mohammadifard M, Hosseini M. Rosmarinic acid attenuates lipopolysaccharide-induced neuroinflammation and cognitive impairment in rats. J Chem Neuroanat. 2021;117(1):102008.

Article  CAS  PubMed  Google Scholar 

Onyekweli CC, Ben-Azu B, Nwangwa EK, Oyovwi OM. Potential effects of epigallocatechin-gallate against high-fat diet-induced memory decline andtesticular abnormalities in male wistar rats. J Appl Sci Environ Manage. 2024;28(10):3079–95.

CAS  Google Scholar 

Tesi EP, Ben-Azu B, Mega OO, Mordi J, Knowledge OO, Awele ED, Rotu RA, Emojevwe V, Adebayo OG, Eneni OA. Kolaviron, a flavonoid‐rich extract ameliorates busulfan‐induced chemo‐brain and testicular damage in male rats through inhibition of oxidative stress, inflammatory, and apoptotic pathways. J Food Biochem. 2022;46(4):e14071.

Article  CAS  PubMed  Google Scholar 

Oyovwi MO, Ben-Azu B, Falajiki FY, Onome OB, Rotu RA, Rotu RA, Oyeleke AA, Okwute GP, Moke EG. D-ribose-L-cysteine exhibits restorative neurobehavioral functions through modulation of neurochemical activities and inhibition oxido-inflammatory perturbations in rats exposed to polychlorinated biphenyl. Naunyn Schmiedebergs Arch Pharmacol. 2024;397(2):931–45.

Article  CAS  PubMed  Google Scholar 

Oyovwi MO, Ugwuishi EW, Udi OA, Atere AD, Rotu AR, Odokuma EI, et al. Epigallocatechin-gallate ameliorates polystyrene microplastics-induced oxido-inflammation and mitochondria-mediated apoptosis in testicular cells via modulation of Nrf2/HO-1,/mTOR/Atg-7, and Cx-43/NOX-1 levels. European Journal of Medicinal Chemistry Reports. 2025;13(1):100243.

Article  CAS